Veeva Systems

New Research Finds 87% of Medtechs Lack Consistent Methods to Share Product Information Across Global Regulatory Teams

Retrieved on: 
Wednesday, November 15, 2023
MDR, Risk, Cross, Regulation, Research, Patient, Veeva Systems, IVDR, Organization, Medical device

PLEASANTON, Calif., Nov. 15, 2023 /PRNewswire/ -- Most medtech companies (87%) can't seamlessly exchange product information between in-country and global regulatory assurance teams, according to the 2023 Regulatory Benchmark Report from Veeva MedTech. Without a standardized and consistent way to share documents globally, organizations can't ensure the reliability or accuracy of product information across markets. This increases compliance risk and can delay the delivery of devices and diagnostics to patients.

Key Points: 
  • Without a standardized and consistent way to share documents globally, organizations can't ensure the reliability or accuracy of product information across markets.
  • A single source for regulatory documents can enable global teams to access real-time information and take proactive action.
  • With this disconnected approach, regulatory teams report they often lack the evidence needed during product claim audits.
  • "The research reveals a significant opportunity for medtechs to unify global regulatory information, a shift that can empower regulatory affairs with data for faster approvals."

New Research Finds 87% of Medtechs Lack Consistent Methods to Share Product Information Across Global Regulatory Teams

Retrieved on: 
Wednesday, November 15, 2023
MDR, Risk, Regulation, Cross, Research, Patient, Veeva Systems, IVDR, Organization, Medical device

BARCELONA, Spain, Nov. 15, 2023 /PRNewswire/ -- Most medtech companies (87%) can't seamlessly exchange product information between in-country and global regulatory assurance teams, according to the 2023 Regulatory Benchmark Report from Veeva MedTech. Without a standardized and consistent way to share documents globally, organizations can't ensure the reliability or accuracy of product information across markets. This increases compliance risk and can delay the delivery of devices and diagnostics to patients.

Key Points: 
  • Without a standardized and consistent way to share documents globally, organizations can't ensure the reliability or accuracy of product information across markets.
  • A single source for regulatory documents can enable global teams to access real-time information and take proactive action.
  • With this disconnected approach, regulatory teams report they often lack the evidence needed during product claim audits.
  • "The research reveals a significant opportunity for medtechs to unify global regulatory information, a shift that can empower regulatory affairs with data for faster approvals."

Veeva Pulse Shows Doctors Opening Up Two-Way Communications Doubles Digital Engagement

Retrieved on: 
Thursday, November 9, 2023
Align Biopharma, Pulse, Veeva Systems, NYSE, Thought, GSK, HCP, Sales

PLEASANTON, Calif., Nov. 9, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today published its latest analysis from the Veeva Pulse Field Trends Report, showing the impact of two-way, digital communication channels on field engagement. Findings reveal that access to compliant chat expands the engagement channel mix, more than doubling digital touchpoints with healthcare professionals (HCPs) while maintaining or increasing in-person meetings.

Key Points: 
  • PLEASANTON, Calif., Nov. 9, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today published its latest analysis from the Veeva Pulse Field Trends Report , showing the impact of two-way, digital communication channels on field engagement.
  • Findings reveal that access to compliant chat expands the engagement channel mix, more than doubling digital touchpoints with healthcare professionals (HCPs) while maintaining or increasing in-person meetings.
  • This two-way communication delivers on HCP requests in real time, creating the foundation for a service-focused engagement model that improves access and efficiency.
  • Veeva Pulse shows that two-way communication channels increase the quality of HCP interactions:
    Inbound channels help to double digital engagement.

Veeva Pulse Shows Doctors Opening Up Two-Way Communications Doubles Digital Engagement

Retrieved on: 
Thursday, November 9, 2023
Align Biopharma, Pulse, GSK, NYSE, Thought, HCP, Sales, Veeva Systems

BARCELONA, Spain, Nov. 9, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today published its latest analysis from the Veeva Pulse Field Trends Report, showing the impact of two-way, digital communication channels on field engagement. Findings reveal that access to compliant chat expands the engagement channel mix, more than doubling digital touchpoints with healthcare professionals (HCPs) while maintaining or increasing in-person meetings.

Key Points: 
  • BARCELONA, Spain, Nov. 9, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today published its latest analysis from the Veeva Pulse Field Trends Report , showing the impact of two-way, digital communication channels on field engagement.
  • Findings reveal that access to compliant chat expands the engagement channel mix, more than doubling digital touchpoints with healthcare professionals (HCPs) while maintaining or increasing in-person meetings.
  • This two-way communication delivers on HCP requests in real time, creating the foundation for a service-focused engagement model that improves access and efficiency.
  • Veeva Pulse shows that two-way communication channels increase the quality of HCP interactions:
    Inbound channels help to double digital engagement.

ACTO DEBUTS AS A MAJOR CONTENDER IN EVEREST GROUP'S FIRST-EVER LIFE SCIENCES NEXT-GENERATION CUSTOMER ENGAGEMENT PLATFORM PEAK MATRIX® ASSESSMENT 2023

Retrieved on: 
Wednesday, November 8, 2023
CX, PEAK, Contender, CEP, Salesforce, Veeva Systems, Risk, Marketing, CRM, Retail

TORONTO, Nov. 8, 2023 /PRNewswire/ - ACTO, the #1 Learning Platform in Life Sciences, today announced that it debuted as a Major Contender in Everest Group's first-ever Life Sciences Next-generation Customer Engagement Platforms (CEP) PEAK Matrix® Assessment 2023.

Key Points: 
  • TORONTO, Nov. 8, 2023 /PRNewswire/ - ACTO, the #1 Learning Platform in Life Sciences, today announced that it debuted as a Major Contender in Everest Group's first-ever Life Sciences Next-generation Customer Engagement Platforms (CEP) PEAK Matrix® Assessment 2023.
  • Technology Capability - ACTO demonstrates a technical sophistication as well as a breadth and depth of functional benefit across its learning platform.
  • Clients appreciate its mobile friendly platform and scenario-based coaching modules coupled with flexible, client-centric engagement and competitive pricing, hence earning it a Major Contender position in Life Sciences Next-generation CEP PEAK Matrix® Assessment 2023."
  • The Everest Group Life Sciences Next-generation CEP PEAK Matrix® Assessment 2023 report provides an objective, data-driven comparative assessment of 23 Life Sciences service and technology providers based on their overall capability and market success.

Aktana Acquires Tact.ai’s Field Engagement and Conversational AI Technology

Retrieved on: 
Wednesday, November 1, 2023
Data Management, Health, Technology, Software, Artificial Intelligence, Pharmaceutical, Biotechnology, Intelligence, Microsoft, Organization, MSL, Veeva Systems, Acquisition, HCP, Microsoft Teams, Patient, Mobile phone

Aktana, Inc., the leader in intelligent customer engagement for the global life sciences industry, today announced the acquisition of Tact.ai’s field engagement and conversational AI technology.

Key Points: 
  • Aktana, Inc., the leader in intelligent customer engagement for the global life sciences industry, today announced the acquisition of Tact.ai’s field engagement and conversational AI technology.
  • As the pioneer of this category and with Tact.ai’s technology, Aktana is now even better positioned to lead this journey toward the future of customer engagement.”
    Powered by Tact.ai technology, Aktana today announced Aktana Copilot, an AI assistant on the mobile phone for life sciences field users.
  • Through Aktana Copilot, customers can capture richer and more tailored engagement data which enables Aktana AI to produce more contextual and effective recommendations for users to have better conversations.
  • “The Strategy Suite that we unveiled at the Aktana Innovation Exchange last month will be enhanced with Aktana Copilot, providing a real-time connection between commercial leaders and the field.

Healthcare Analytics Market size to grow by USD 66.53 billion growth between 2023 - 2028| Driven by Growing integration of Big Data with healthcare analytics- Technavio

Retrieved on: 
Tuesday, October 31, 2023
Cloud, Government, Big data, Service, MedinTux, SAS Institute, Organization, Maintenance, OpenHospital, Data management, Learning, Environment, Growth, Veeva Systems, Hardware, OpenEMR, Health, USD, Component, Patient, OpenMRS, Pharmaceutical industry, Nursing, Software, Geography, Oracle

The market is experiencing notable growth driven by the increasing integration of Big Data into healthcare analytics.

Key Points: 
  • The market is experiencing notable growth driven by the increasing integration of Big Data into healthcare analytics.
  • This transformation is reshaping data management, analysis, and utilization across various industries, and healthcare is no exception, generating substantial data.
  • Get deeper insights into the market size, current market scenario, future growth opportunities, major growth driving factors, the latest trends, and much more.
  • Buy full report here
    A significant challenge impeding market growth is the presence of open-source healthcare analytics solutions.

MedaSystems Secures Seed Financing to Modernize Global Access to Investigational Medicine

Retrieved on: 
Thursday, October 12, 2023
Health Technology, Technology, Pharmaceutical, Practice Management, Managed Care, Professional Services, General Health, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Data Analytics, Health, Research, Expanded access, Workload, Physician, Machine learning, User-Managed Access, Automation, Veeva Systems, Software as a service, Clinical trial, Pharmacist, Patient, Microsoft Access, Pharmaceutical industry, Medical device, Nursing

MedaSystems, developer of the only purpose-built pharma-physician network to provide patients with access to pre-approval medicine*, today announced the completion of a seed funding round.

Key Points: 
  • MedaSystems, developer of the only purpose-built pharma-physician network to provide patients with access to pre-approval medicine*, today announced the completion of a seed funding round.
  • The MedaSystems SaaS platform streamlines collaboration between medical affairs, clinical operations, regulatory and shipping teams internally, and physicians and their staff, externally, enabling the rapid processing of treatment inquiries and capture of real-world data.
  • The platform provides significant benefits to various stakeholders:
    Sponsors (pharmaceutical manufacturers) gain significant processing speed and efficiency.
  • The platform enables the capture of real-world data which speeds drug discovery, expedites regulatory submission and informs the design of more effective clinical trials.

Veeva to Host Virtual Investor Day on Nov. 9, 2023

Retrieved on: 
Thursday, October 5, 2023
NYSE, Veeva Systems, Reinsurance, Broadcasting, Cryptocurrency

PLEASANTON, Calif., Oct. 5, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will host its investor day virtually on Thursday, November 9, 2023.

Key Points: 
  • PLEASANTON, Calif., Oct. 5, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will host its investor day virtually on Thursday, November 9, 2023.
  • The event will begin at 9:00 a.m. PT and will conclude at approximately 11:00 a.m. PT.
  • Veeva will broadcast the presentations live on the company's investor relations website, ir.veeva.com , where a link to the archived webcast will also be available after the event.

LEO Pharma Connects Affiliates with Veeva Vault Safety to Transform Safety Operations

Retrieved on: 
Tuesday, October 3, 2023
Cloud, Safety, Case management, Veeva Systems, Drug development, Leo Pharma, Patient, NYSE, Pharmacovigilance, Pharmaceutical industry

PLEASANTON, Calif., Oct. 3, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that LEO Pharma, a global leader in medical dermatology, is using Veeva Vault Safety to optimize its safety operations. With this foundation, the company can seamlessly incorporate affiliates into safety workflows, boost operational efficiencies, ensure compliance, and unify its global pharmacovigilance data on one platform.

Key Points: 
  • PLEASANTON, Calif., Oct. 3, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that LEO Pharma , a global leader in medical dermatology, is using Veeva Vault Safety to optimize its safety operations.
  • "LEO Pharma is deeply committed to the safety of patients using its products," said Pilar Carrero, vice president of global safety at LEO Pharma.
  • Vault Safety is helping LEO Pharma improve oversight of case intake, processing, submission, and distribution while simplifying safety workflows and eliminating data reconciliation with affiliates and partners.
  • "Veeva is happy to partner with LEO Pharma to make its safety operations simpler and more effective."